Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-06-16

Clinical Trial Update: Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating empagliflozin in adults with type 2 diabetes and renal impairment has completed. The results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Jardiance (empagliflozin) (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2, Renal Insufficiency | Phase 3 | Status: COMPLETED | Results posted: 2014-06-16